Skip to main content
Skip to content
1 duplicate copy in the archive
Case File
d-20460House Oversight

New Leaf Biopharma Fund Overview – Investment Track Record Summary

Other

The passage is a promotional summary of a biopharmaceutical investment fund, listing past deals and exits. It contains no allegations, financial flow details, or connections to high‑profile public off Describes New Leaf's network of senior pharma executives, scientists, and investors. Lists several portfolio companies and exit multiples (e.g., Pearl Therapeutics sold to AstraZeneca). Mentions rest

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024045
Pages
1
Persons
3
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.